These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Experimental study on the effect of cyclosporine A drug delivery system implanted in anterior chamber on high-risk corneal graft rejection. Xie L; Shi W; Wang Z; Liu Z Zhonghua Yan Ke Za Zhi; 2002 Jul; 38(7):422-5. PubMed ID: 12411004 [TBL] [Abstract][Full Text] [Related]
24. Long-term effects of topical cyclosporine A treatment after penetrating keratoplasty. Inoue K; Amano S; Kimura C; Sato T; Fujita N; Kagaya F; Kaji Y; Oshika T; Tsuru T; Araie M Jpn J Ophthalmol; 2000; 44(3):302-5. PubMed ID: 10913651 [TBL] [Abstract][Full Text] [Related]
26. [Efficacy of topical cyclosporine A on keratoplasty rejection in rats]. Zhang W; Pan Z; Zhai C Zhonghua Yan Ke Za Zhi; 2001 Mar; 37(2):140-3. PubMed ID: 11864411 [TBL] [Abstract][Full Text] [Related]
27. Efficacy of postoperative immunosuppression after keratoplasty in herpetic keratitis. Maier AK; Ozlügedik S; Rottler J; Heussen FM; Klamann MK; Huber KK; Joussen AM; Winterhalter S Cornea; 2011 Dec; 30(12):1398-405. PubMed ID: 21996945 [TBL] [Abstract][Full Text] [Related]
28. Mycophenolate mofetil versus cyclosporin A in high risk keratoplasty patients: a prospectively randomised clinical trial. Reis A; Reinhard T; Voiculescu A; Kutkuhn B; Godehardt E; Spelsberg H; Althaus C; Sundmacher R Br J Ophthalmol; 1999 Nov; 83(11):1268-71. PubMed ID: 10535855 [TBL] [Abstract][Full Text] [Related]
29. [Interim results from the prospective "Erlanger Non-high-risk Penetrating Keratoplasty Study" in 207 patients]. Graupner M; Seitz B; Langenbucher A; Martus P; Blüthner K; Nguyen NX; Wenkel H; Küchle M Klin Monbl Augenheilkd; 2000 Sep; 217(3):163-70. PubMed ID: 11076347 [TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of microspheres of cyclosporin A, a new systemic formulation, to prevent corneal graft rejection in rats. Vallelado AI; López MI; Calonge M; Sánchez A; Alonso MJ Curr Eye Res; 2002 Jan; 24(1):39-45. PubMed ID: 12187493 [TBL] [Abstract][Full Text] [Related]
31. [Cyclosporin A combined with dexamethasone in preventing and treating immune rejection after penetrating keratoplasty]. Xi XH; Qin B; Jiang DY Hunan Yi Ke Da Xue Xue Bao; 2003 Dec; 28(6):627-30. PubMed ID: 15804077 [TBL] [Abstract][Full Text] [Related]
32. The effects of donor age on the outcome of penetrating keratoplasty in adults. Palay DA; Kangas TA; Stulting RD; Winchester K; Litoff D; Krachmer JH Ophthalmology; 1997 Oct; 104(10):1576-9. PubMed ID: 9331193 [TBL] [Abstract][Full Text] [Related]
33. Long-term outcome of systemic cyclosporine treatment following penetrating keratoplasty. Inoue K; Kimura C; Amano S; Sato T; Fujita N; Kagaya F; Kaji Y; Tsuru T; Araie M Jpn J Ophthalmol; 2001; 45(4):378-82. PubMed ID: 11485770 [TBL] [Abstract][Full Text] [Related]
34. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. Abramowicz D; Del Carmen Rial M; Vitko S; del Castillo D; Manas D; Lao M; Gafner N; Wijngaard P; J Am Soc Nephrol; 2005 Jul; 16(7):2234-40. PubMed ID: 15917338 [TBL] [Abstract][Full Text] [Related]
35. Long-term Functional and Anatomic Outcomes of Repeat Graft After Optically Failed Therapeutic Keratoplasty. Srujana D; Kaur M; Urkude J; Rathi A; Sharma N; Titiyal JS Am J Ophthalmol; 2018 May; 189():166-175. PubMed ID: 29550189 [TBL] [Abstract][Full Text] [Related]
36. [Basiliximab following penetrating risk-keratoplasty--a prospective randomized pilot study]. Birnbaum F; Jehle T; Schwartzkopff J; Sokolovska Y; Böhringer D; Reis A; Reinhard T Klin Monbl Augenheilkd; 2008 Jan; 225(1):62-5. PubMed ID: 18236372 [TBL] [Abstract][Full Text] [Related]
37. Topical corticosteroids with topical cyclosporine A versus topical corticosteroids alone for immunological corneal graft rejection. Marques RE; Leal I; Guerra PS; Barão RC; Quintas AM; Rodrigues W Eur J Ophthalmol; 2022 May; 32(3):1469-1481. PubMed ID: 34231398 [TBL] [Abstract][Full Text] [Related]
38. Combined intravenous pulse methylprednisolone and oral cyclosporine A in the treatment of corneal graft rejection: 5-year experience. Young AL; Rao SK; Cheng LL; Wong AK; Leung AT; Lam DS Eye (Lond); 2002 May; 16(3):304-8. PubMed ID: 12032722 [TBL] [Abstract][Full Text] [Related]
39. Systemic immunosuppression with mycophenolate mofetil to prevent corneal graft rejection after high-risk penetrating keratoplasty: a 2-year follow-up study. Szaflik JP; Major J; Izdebska J; Lao M; Szaflik J Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):307-14. PubMed ID: 26553197 [TBL] [Abstract][Full Text] [Related]
40. Efficacy of topical cyclosporine A 2% in prevention of graft rejection in high-risk keratoplasty: a randomized controlled trial. Sinha R; Jhanji V; Verma K; Sharma N; Biswas NR; Vajpayee RB Graefes Arch Clin Exp Ophthalmol; 2010 Aug; 248(8):1167-72. PubMed ID: 20414783 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]